Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin-strengthened BUCY for high-risk AML
NCT01766375Phase 3Unknown
- Sponsor
- Guangxi Medical University
- Start
- Aug 2012
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of idarubicin in acute myeloid leukemia (AML), sponsored by Guangxi Medical University. Status: unknown.
02
Drugs
idarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01766375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01766375.